Di Raimondo F, Palumbo G A, Romeo M A, Galvagno F, Stagno F, Morabito F, Giustolisi R
Institute of Hematology, University of Catania, Italy.
Leuk Lymphoma. 1997 Jun;26(1-2):115-9. doi: 10.3109/10428199709109165.
Taxol is a new antimicrotubule agent that, besides a well known efficacy against solid tumors, has shown activity in non-Hodgkin's lymphomas too. We therefore investigated its in vitro cytotoxic activity against cells from patients affected by chronic lymphocytic leukemia (CLL). Peripheral blood lymphocytes from 46 CLL patients were incubated for four days with Taxol at doses ranging from 0.01 to 10 mM and the cytotoxicity was evaluated by a colorimetric method (XTT). In most samples Taxol was inactive and the IC50 was > 10 mM in 40 out of 46 patients. It is worthwhile noting that four of the six in vitro responsive patients had unfavourable clinical features. In three unresponsive patients we also observed that Taxol was not able to induce apoptosis in vitro. In conclusion, based on in vitro data, it seems that Taxol is not an active drug in standard CLL but we cannot exclude some efficacy in other more rapidly proliferating lymphoproliferative disorders.
紫杉醇是一种新型抗微管药物，除了对实体瘤有众所周知的疗效外，在非霍奇金淋巴瘤中也显示出活性。因此，我们研究了其对慢性淋巴细胞白血病（CLL）患者细胞的体外细胞毒活性。将46例CLL患者的外周血淋巴细胞与剂量范围为0.01至10 mM的紫杉醇孵育4天，并通过比色法（XTT）评估细胞毒性。在大多数样本中，紫杉醇无活性，46例患者中有40例的半数抑制浓度（IC50）>10 mM。值得注意的是，6例体外反应性患者中有4例具有不良临床特征。在3例无反应的患者中，我们还观察到紫杉醇在体外不能诱导细胞凋亡。总之，根据体外数据，紫杉醇似乎不是标准CLL中的活性药物，但我们不能排除其在其他增殖较快的淋巴增殖性疾病中的某些疗效。
